magicmine Insmed ( NASDAQ: INSM ) said it plans to submit a New Drug Application to the U.S. FDA for brensocatib as a treatment for the chronic lung condition bronchiectasis in Q4.
The decision follows additional positive results from the phase 3 ASPEN study. In late May, the company announced the candidate met its primary endpoint . The new 52-week forced expiratory volume over one second (FEV1) data indicates that brensocatib is associated with significantly less decline in lung function compared to placebo.
More on Insmed Insmed Strikes Gold With Phase 3 Bronchiectasis Win (Rating Upgrade) Insmed announces pricing of $650M public offering Insmed intends to raise $500M via equity offering Insmed, Inc. (INSM) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Insmed.